WCN25-1035 Association between Anti-Erythropoietin Receptor Antibodies and Cardiac Function in Patients on Hemodialysis: A Multi-center Cross-Sectional Study
Cardiac dysfunction is an important prognostic predictor of cardiovascular mortality in patients on hemodialysis (HD). Erythropoietin (EPO) has been reported to improve cardiac function by binding to the EPO receptor (EPOR) on cardiomyocytes. This study investigated whether anti-EPOR antibodies were associated with left ventricular cardiac function (mass index [LVMI] and ejection fraction [LVEF]) in patients undergoing HD.
Authors
- Yasunori Iwata (ORCID: https://orcid.org/0000-0002-4756-5207)
- Kunihiro Ishioka (ORCID: https://orcid.org/0000-0001-9129-5075)
- Shuzo Kobayashi (ORCID: https://orcid.org/0000-0003-2373-814X)
- Takayasu Ohtake (ORCID: https://orcid.org/0000-0002-7009-161X)
- Megumi Oshima (ORCID: https://orcid.org/0000-0002-4108-5229)
- Sumi Hidaka (ORCID: https://orcid.org/0000-0002-1576-0868)
- Norihiko Sakai (ORCID: https://orcid.org/0000-0001-7245-9716)
- Takashi Wada (ORCID: https://orcid.org/0000-0002-0123-3645)
- Miho Shimizu (ORCID: https://orcid.org/0000-0002-7737-935X)
- Yoshitaka Koshino
- Machiko Oka
- Shinji Kitajima (ORCID: https://orcid.org/0000-0002-6532-6496)
- Yasuhiro Mochida
- Hidekazu Moriya (ORCID: https://orcid.org/0000-0002-3252-2976)
- Akinori Hara (ORCID: https://orcid.org/0000-0002-0399-1474)
- Tadashi Toyama (ORCID: https://orcid.org/0000-0003-0162-6286)
Institutions
- Kanazawa University (JP)
- Shonan Kamakura General Hospital (JP)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.617
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00